NUR 6011 Exam 1 Actual Exam V3 | NUR 6011 Advance Pharmacology
(NUR6011 Exam 1) | William Paterson University
1. A patient is prescribed a medication with a very high volume of distribution (Vd). Which of
the following statements best describes the clinical implication of this finding?
A. The drug is likely confined primarily to the plasma compartment.
B. The drug has extensively distributed into peripheral tissues.
C. The drug is highly protein-bound and remains in the vascular space.
D. The drug will be rapidly eliminated by the kidneys.
Answer: B
Rationale: A high volume of distribution indicates that the drug has left the plasma and
distributed extensively into tissues such as fat or muscle. This often means the drug is lipid-
soluble and may require a larger loading dose to achieve therapeutic plasma
concentrations. Understanding Vd is crucial for APRNs when determining initial dosing
strategies for complex patients.
2. When a drug is an inducer of the Cytochrome P450 (CYP450) enzyme system, what is the
expected effect on a co-administered ‘substrate’ drug?
A. Increased plasma levels and potential toxicity of the substrate.
B. Decreased metabolism and prolonged half-life of the substrate.
C. Increased metabolism and decreased plasma levels of the substrate.
D. No significant change in the pharmacokinetic profile of the substrate.
Answer: C
Rationale: Enzyme inducers speed up the metabolic activity of the CYP450 system, leading
to faster breakdown of other medications that use the same pathway. This results in lower
therapeutic levels of the substrate drug, potentially leading to treatment failure. APRNs
must monitor for reduced efficacy when an inducer, such as rifampin or St. John’s Wort, is
added to a regimen.
3. An 85-year-old patient is being prescribed a new medication. According to the Beers
Criteria, which pharmacological change in the elderly significantly increases the risk of drug
toxicity?
A. Increased total body water.
B. Increased hepatic blood flow.
C. Decreased percentage of body fat.
,D. Reduced glomerular filtration rate (GFR).
Answer: D
Rationale: Aging is associated with a physiological decline in renal function, which
decreases the clearance of many medications. This reduction in GFR means drugs remain in
the system longer, increasing the risk of accumulation and toxicity. The Beers Criteria
highlights the need for renal-based dose adjustments to ensure safety in the geriatric
population.
4. Which term describes the process where the liver metabolizes a drug significantly before it
reaches systemic circulation following oral administration?
A. Enterohepatic recirculation.
B. Bioavailability shift.
C. First-pass effect.
D. Passive diffusion.
Answer: C
Rationale: The first-pass effect occurs when an oral medication is absorbed from the GI
tract into the portal circulation and metabolized by the liver before reaching the rest of the
body. This can significantly reduce the amount of active drug available to produce an effect.
APRNs often choose alternative routes, such as sublingual or IV, to bypass this effect for
drugs with high first-pass metabolism.
5. A patient with hypoalbuminemia is prescribed a highly protein-bound drug. What is the
primary concern for the APRN?
A. The drug will be unable to cross the blood-brain barrier.
B. There will be an increased fraction of ‘free’ active drug in the plasma.
C. The drug will be absorbed more slowly from the gut.
D. The drug will have a shorter duration of action due to rapid binding.
Answer: B
Rationale: Only the unbound or ‘free’ portion of a drug is pharmacologically active and
able to produce a therapeutic effect. In patients with low albumin levels, there are fewer
binding sites, leading to higher levels of free drug and an increased risk of adverse effects.
Clinical monitoring must be intensified in patients with malnutrition or liver disease who
are taking highly bound drugs like warfarin.
6. The APRN is calculating the half-life of a drug. If a drug has a half-life of 4 hours, how long
will it take to reach steady-state concentration with regular dosing?
A. 4 to 8 hours.
, B. 16 to 20 hours.
C. 10 to 12 hours.
D. 24 to 36 hours.
Answer: B
Rationale: Steady state is generally reached after approximately 4 to 5 half-lives of a drug.
With a half-life of 4 hours, multiplying by 4 or 5 yields a range of 16 to 20 hours. This
principle is vital for determining when to measure peak and trough levels to assess
therapeutic efficacy.
7. Which of the following describes a ‘Prodrug’?
A. A drug that is excreted unchanged by the kidneys.
B. A medication that is active upon administration but becomes toxic when metabolized.
C. A drug that acts as a competitive antagonist at the receptor site.
D. An inactive compound that must be metabolized to become pharmacologically active.
Answer: D
Rationale: Prodrugs are designed to improve absorption or decrease initial toxicity,
relying on hepatic enzymes to convert them into their active form. If a patient has severe
hepatic impairment, the conversion may not occur, rendering the medication ineffective.
Examples include codeine, which must be converted to morphine by CYP2D6 to provide
analgesia.
8. A patient experiences an ‘Idiosyncratic’ drug reaction. How should the APRN define this to
the patient?
A. A predictable side effect related to the dose.
B. An allergic reaction mediated by IgE antibodies.
C. An uncommon and unpredictable response often caused by genetic differences.
D. A secondary effect that occurs only after long-term use.
Answer: C
Rationale: Idiosyncratic reactions are unique to the individual and do not follow the
typical pharmacological profile of the drug. These are often rooted in genetic
polymorphisms that affect how the individual’s body processes the substance. Because they
are unpredictable, they require immediate cessation of the drug and careful
documentation.
9. Which pharmacokinetic process is primarily affected by the pH of the gastric environment?
A. Metabolism.
(NUR6011 Exam 1) | William Paterson University
1. A patient is prescribed a medication with a very high volume of distribution (Vd). Which of
the following statements best describes the clinical implication of this finding?
A. The drug is likely confined primarily to the plasma compartment.
B. The drug has extensively distributed into peripheral tissues.
C. The drug is highly protein-bound and remains in the vascular space.
D. The drug will be rapidly eliminated by the kidneys.
Answer: B
Rationale: A high volume of distribution indicates that the drug has left the plasma and
distributed extensively into tissues such as fat or muscle. This often means the drug is lipid-
soluble and may require a larger loading dose to achieve therapeutic plasma
concentrations. Understanding Vd is crucial for APRNs when determining initial dosing
strategies for complex patients.
2. When a drug is an inducer of the Cytochrome P450 (CYP450) enzyme system, what is the
expected effect on a co-administered ‘substrate’ drug?
A. Increased plasma levels and potential toxicity of the substrate.
B. Decreased metabolism and prolonged half-life of the substrate.
C. Increased metabolism and decreased plasma levels of the substrate.
D. No significant change in the pharmacokinetic profile of the substrate.
Answer: C
Rationale: Enzyme inducers speed up the metabolic activity of the CYP450 system, leading
to faster breakdown of other medications that use the same pathway. This results in lower
therapeutic levels of the substrate drug, potentially leading to treatment failure. APRNs
must monitor for reduced efficacy when an inducer, such as rifampin or St. John’s Wort, is
added to a regimen.
3. An 85-year-old patient is being prescribed a new medication. According to the Beers
Criteria, which pharmacological change in the elderly significantly increases the risk of drug
toxicity?
A. Increased total body water.
B. Increased hepatic blood flow.
C. Decreased percentage of body fat.
,D. Reduced glomerular filtration rate (GFR).
Answer: D
Rationale: Aging is associated with a physiological decline in renal function, which
decreases the clearance of many medications. This reduction in GFR means drugs remain in
the system longer, increasing the risk of accumulation and toxicity. The Beers Criteria
highlights the need for renal-based dose adjustments to ensure safety in the geriatric
population.
4. Which term describes the process where the liver metabolizes a drug significantly before it
reaches systemic circulation following oral administration?
A. Enterohepatic recirculation.
B. Bioavailability shift.
C. First-pass effect.
D. Passive diffusion.
Answer: C
Rationale: The first-pass effect occurs when an oral medication is absorbed from the GI
tract into the portal circulation and metabolized by the liver before reaching the rest of the
body. This can significantly reduce the amount of active drug available to produce an effect.
APRNs often choose alternative routes, such as sublingual or IV, to bypass this effect for
drugs with high first-pass metabolism.
5. A patient with hypoalbuminemia is prescribed a highly protein-bound drug. What is the
primary concern for the APRN?
A. The drug will be unable to cross the blood-brain barrier.
B. There will be an increased fraction of ‘free’ active drug in the plasma.
C. The drug will be absorbed more slowly from the gut.
D. The drug will have a shorter duration of action due to rapid binding.
Answer: B
Rationale: Only the unbound or ‘free’ portion of a drug is pharmacologically active and
able to produce a therapeutic effect. In patients with low albumin levels, there are fewer
binding sites, leading to higher levels of free drug and an increased risk of adverse effects.
Clinical monitoring must be intensified in patients with malnutrition or liver disease who
are taking highly bound drugs like warfarin.
6. The APRN is calculating the half-life of a drug. If a drug has a half-life of 4 hours, how long
will it take to reach steady-state concentration with regular dosing?
A. 4 to 8 hours.
, B. 16 to 20 hours.
C. 10 to 12 hours.
D. 24 to 36 hours.
Answer: B
Rationale: Steady state is generally reached after approximately 4 to 5 half-lives of a drug.
With a half-life of 4 hours, multiplying by 4 or 5 yields a range of 16 to 20 hours. This
principle is vital for determining when to measure peak and trough levels to assess
therapeutic efficacy.
7. Which of the following describes a ‘Prodrug’?
A. A drug that is excreted unchanged by the kidneys.
B. A medication that is active upon administration but becomes toxic when metabolized.
C. A drug that acts as a competitive antagonist at the receptor site.
D. An inactive compound that must be metabolized to become pharmacologically active.
Answer: D
Rationale: Prodrugs are designed to improve absorption or decrease initial toxicity,
relying on hepatic enzymes to convert them into their active form. If a patient has severe
hepatic impairment, the conversion may not occur, rendering the medication ineffective.
Examples include codeine, which must be converted to morphine by CYP2D6 to provide
analgesia.
8. A patient experiences an ‘Idiosyncratic’ drug reaction. How should the APRN define this to
the patient?
A. A predictable side effect related to the dose.
B. An allergic reaction mediated by IgE antibodies.
C. An uncommon and unpredictable response often caused by genetic differences.
D. A secondary effect that occurs only after long-term use.
Answer: C
Rationale: Idiosyncratic reactions are unique to the individual and do not follow the
typical pharmacological profile of the drug. These are often rooted in genetic
polymorphisms that affect how the individual’s body processes the substance. Because they
are unpredictable, they require immediate cessation of the drug and careful
documentation.
9. Which pharmacokinetic process is primarily affected by the pH of the gastric environment?
A. Metabolism.
